JenaValve’s Trilogy TAVR Commercial and Clinical Initiatives Supported by $100 Million in Series C Financing

August 31, 2022—JenaValve Technology, Inc., a developer of transcatheter aortic valve replacement (TAVR) systems, announced that it has completed the initial closing of a $100 million Series C financing.

According to the company, proceeds from the financing will enable JenaValve to complete its investigational device exemption (IDE) premarket approval study to obtain FDA approval for its Trilogy heart valve system for high surgical-risk patients with symptomatic, severe aortic regurgitation (AR). The company announced IDE approval for the ALIGN-AR pivotal trial in August 2021.

In addition, JenaValve will use the proceeds to increase its real-world data development initiatives in Europe, where the Trilogy system received CE Mark approval in May 2021. On June 28, 2022, the company announced results from the first commercial implantations in Europe with the Trilogy system in high-surgical-risk patients with severe symptomatic aortic stenosis or AR.

The funds will also support expansion of JenaValve’s worldwide manufacturing capabilities.

The financing was led by Bain Capital Life Sciences and included participation from existing investors Andera Partners, Valiance Advisors, Gimv, Cormorant Asset Management, RMM, and Venture Incubator. New investors joining the syndicate included Pictet Alternative Advisors SA, Qatar Investment Authority, Innovatus Capital Partners, and Peijia Medical Limited.